An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists

data for An orally angiotensin - (1 – 7) inclusion compound reduce time to reaction in 2 stroop task and modify heart rate variability after continuous test in mountain 3 bike cyclists,

Recently our group showed that hydroxypropyl β-cyclodextrin (HPβ-CD)-Angiotensin-(1-7) (HPβ-CD-Ang-[1-7]) oral formulation affects performance and decreases the perceived effort of mountain bike (MTB) athletes.

Twenty-one male MTB practitioners were divided into a continuous protocol time trial and repeated sprint groups. Three hours before a 20-km cycling time trial or 4×30-s repeated all-out sprints on a leg cycle ergometer, the athletes received HPβ-CD-Ang-(1-7) (0.8 mg) or HPβ-CD-placebo (only HPβ-CD) oral capsules over a 7-day interval randomized crossover design. At rest and immediately after the exercise protocol, the ratings of perceived recovery and the visual analog scale were assessed, and the volunteers completed the Stroop task (ST). Heart rate variability was measured at rest and peak effort. There were no differences in the perceived variables. The ST showed that HPβ-CD-Ang-(1-7) supplementation reduced the reaction time (rest 1032±331 ms vs. after protocol 902±286 ms, p=0.05) after the continuous time trial. The withdrawal of the parasympathetic components in the peak effort to the continuous protocol was not different from that of rest in the HPβ-CD-Ang-(1-7) condition. The results are pioneering, especially in humans, but indicate that Angiotensin-(1-7) potentially affects reaction time and the parasympathetic withdrawal after continuous protocol time trial.